JBIO - Aerovate Therapeutics, Inc.

14.05
0.170   1.210%

Share volume: 299,346
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$13.88
0.17
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 19%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.64%
1 Month
-2.90%
3 Months
4.07%
6 Months
84.38%
1 Year
466.53%
2 Year
-43.28%
Key data
Stock price
$14.05
P/E Ratio 
0.00
DAY RANGE
$13.44 - $14.34
EPS 
-$1.32
52 WEEK RANGE
$2.24 - $17.71
52 WEEK CHANGE
$466.53
MARKET CAP 
281.569 M
YIELD 
27.81%
SHARES OUTSTANDING 
46.004 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
0.68
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$285,067
AVERAGE 30 VOLUME 
$239,827
Company detail
CEO: Timothy P. Noyes
Region: US
Website: aerovatetx.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

Recent news